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Abstract: A new approach for hyperpolarized 129Xe molecular 
sensors is explored using paramagnetic relaxation agents that can 
be deactivated upon chemical or enzymatic reaction with an analyte. 
Cryptophane encapsulated 129Xe within the vicinity of the 
paramagnetic center experiences fast relaxation that, through 
chemical exchange of xenon atoms between cage and solvent pool, 
causes accelerated hyperpolarized 129Xe signal decay in the 
dissolved phase. In this work, the relaxivity of GadoliniumIII-DOTA 
on 129Xe in the solvent was increased eightfold through tethering of 
the paramagnetic molecule to a cryptophane cage. This potent 
relaxation agent can be ‘turned off’ specifically for 129Xe through 
chemical reactions that spatially separate the GdIII centre from the 
attached cryptophane cage. Unlike 129Xe chemical shift based 
sensors, the new concept does not require high spectral resolution 
and may lead to a new generation of responsive contrast agents for 
molecular MRI. 
Molecular imaging enables the in vivo detection of the spatial 
distribution of specific target molecules that serve as ‘biomarkers’ 
for organ physiology. Imaging of biomarkers allows for the early 
detection of disease, for better monitoring of treatment, and for 
drug development. Among the strategies to enable molecular 
MRI[1] the hyperpolarized (hp) 129Xe biosensor concept 
pioneered by Pines, Wemmer, and co-workers[2] is a promising 
candidate due to xenon’s non-toxicity, the simplicity of the 
corresponding NMR spectra, and its solubility in blood plasma 
and tissue.[3] Hp 129Xe biosensors utilize an encapsulating agent, 
such as cryptophane cages, that can reversibly bind Xe atoms 
with fast rates of exchange. The large chemical shift range of 
129Xe leads to a distinguishable signal separation between 
encapsulated xenon atoms in the hydrophobic cavity and xenon 
in the solvent (not visible in Fig. 1b due to line broadening, see 
Fig. S2 in Supporting Information). Furthermore, cryptophanes 
can be functionalized with suitable bioactive ligands to serve as 
biosensor molecules that interact with a particular biomarker, 
typically a protein. The biosensor – biomarker interaction further 
alters the environment of the encapsulated 129Xe, giving rise to a 
different chemical shift that can be observed by NMR 
spectroscopy. This was originally shown with biotin-
functionalized cryptophane as a sensor for the protein avidin[2a] 
for which biotin has a very high affinity. 
  
 
Figure 1. A) Hp 129Xe NMR spectrum of a 1:1 v/v water/acetonitrile (H2O/ACN) 
solution containing 0.33 mM GdDOTA. The hp 129Xe signal intensity of the 
dissolved phase (189.6 ppm) - and through exchange, the intensity of the gas 
phase (0 ppm) - is only moderately affected by the relaxation agent because 
the exposure time of the xenon atoms to the paramagnetic center is very 
limited. B) Hp 129Xe NMR spectrum of 0.035 mM cryptophane-A tethered to 
GdDOTA in H2O/ACN solution. Encapsulated 129Xe is not detected because of 
severe line broadening. This molecule serves as a strong relaxation agent, 
specifically for 129Xe, due to prolonged duration of 129Xe encapsulation in the 
close vicinity to the paramagnetic relaxation center. The effect of fast 
relaxation (or depolarization) of encapsulated hp 129Xe is transferred via 
chemical exchange to the dissolved phase (189.3 ppm) where an accelerated 
decay of the 129Xe(sol) signal is observed. 
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Hyperpolarized 129Xe Chemical Exchange Saturation 
Transfer (HyperCEST)[2c] improves the hp 129Xe biosensor 
detection limit by orders of magnitude.[4] HyperCEST is achieved 
by selective irradiation (i.e. saturation) at the NMR frequency of 
the encapsulated 129Xe signal that depolarizes its hp spin state. 
Chemical exchange continuously transfers depolarized 129Xe 
from the cage to the dissolved phase and accelerates the decay 
of the dissolved phase signal.  
Molecular sensing with HyperCEST usually relies on the 
small 129Xe chemical shift differences created by biosensor – 
biomarker interactions that are typically in the 2-3 ppm range, 
with exceptional cases up to 8 ppm.[6] Although hp 129Xe 
biosensors enable a host of biomolecular NMR applications,[3a, 3b, 
6-7] including in vitro MRI for cell tracking [8] and in vivo organ 
uptake of functionalized nanoparticles,[9] in vivo MRI usage in 
complex organisms such as vertebrates is generally limited by 
the achievable low spectral resolution. This is a limitation 
wherever chemical shift is required to distinguish between a 
binding (or cleaving) event and unspecific interaction (i.e. 
typically non-reacted sensors that are still present to a significant 
extent). A very promising advancement has been reported very 
recently that does not require high spectral resolution because 
the unspecific background was very small. HyperCEST enabled 
imaging of cell-surface glycans at nanomolar concentrations in 
live-cell bioreactors[5]. However, wherever the biosensor 
molecules interacting with biomarker molecules need to be 
distinguished from a significant amount of biosensors that have 
not been bound, cleaved, or otherwise reacted biomarker 
specifically, imaging will likely have to cope with small chemical 
shift differences between the two biosensor moieties. 
This proof-of-concept study presents a different approach 
for hp 129Xe biosensors, sketched in Fig. 1b, using paramagnetic 
relaxation instead of the chemical shift. Paramagnetic relaxation 
causes rapid decay of the hp signal. Paramagnetic metal 
centers are therefore usually avoided for hp MRI probes, except 
for the generation of negative contrast through shortened T1, T2, 
or T2* times.[10] Note that upon submission of this manuscript, 
the authors learned that a paramagnetic relaxation based 
hp129Xe biosensor concept has also been reported by Wemmer, 
Pines, and co-workers[11]. The new hp 129Xe biosensor concept 
in this work utilizes ‘switchable’ paramagnetic relaxation. 
Chemical sensing will be based on chemical changes brought 
about by target molecules that ‘deactivate’ the responsive 
relaxation agent. Hp 129Xe will be administered after sufficient 
time has passed to allow for any deactivation to occur that 
causes positive MRI contrasts. NMR relaxation studies with the 
model sensor CrA-GdDOTA were used to gain insights into the 
magnitude of the relaxivity change and hence to explore the 
concept feasibility. 
. 
Results and Discussion. A 1:1 v/v mixture of water with 
acetonitrile (H2O/ACN) was found to be an acceptable solvent 
for the model sensor, DOTA itself, and GdIII but also for the 
xenon atoms. As shown in Fig. 2, the 129Xe relaxation rates, R1 = 
1/T1, were measured as function of the concentration of the 
various relaxation agents, [Rx], to determine the relaxivity of the 
respective agents. The relaxivity of GdDOTA for 129Xe(sol) was 
determined as R1/[Rx] = 0.0515 s-1mM-1 (see Fig. 3). The 
approximately 150 fold reduced relaxivity of gadolinium for 
129Xe(sol) compared to that for H2O protons (7.66 s-1mM-1 – see 
Fig. 3) is caused in part by xenon’s lower gyromagnetic ratio  
that contributes to an approximately 13 fold reduced relaxivity 
due to the  dependence of paramagnetic relaxation.[12],[13] In 
addition, H2O protons experience further accelerated relaxation 
because of direct coordination of water with the GdIII center in 
DOTA complexes.[1] 
A 1 mM GdDOTA solution causes only slow hp 129Xe(sol) 
relaxation, with T1 = 19 s, that will have little effect on the overall 
129Xe relaxation behavior in vivo. For example, typical relaxation 
times for hp 129Xe(aq) in blood range from approximately 2.7 to 
7.9 s, depending on blood oxygenation.[14] In lung tissue and 
blood, rapid exchange with the gas phase prolongs the 129Xe(aq) 
relaxation times up to 20 s.[13] 
For CrA-GdDOTA, where GdDOTA is tethered to the 
cryptophane cage, the GdIII relaxivity for 129Xe(sol) increased 
more than 8 times to R1/[Rx] = 0.416 s-1mM-1. The large 
relaxivity enhancement is likely caused by fast relaxation of 
encapsulated 129Xe in close proximity to the paramagnetic 
GdDOTA. Paramagnetic relaxation follows an r-6 dependence,[12] 
where r is the distance between the nuclear spin (here, of 
encapsulated 129Xe) and the paramagnetic center. Chemical 
exchange between Xe in cages and solution transfers the 
relaxation effect and leads to accelerated R1 rates for the 
dissolved phase 129Xe(sol). The relatively small 129Xe(sol) chemical 
shift dependence on [Rx] is listed in Fig. 3A and Fig. 3B for 
comparison. 
 
Figure 2. Relaxation rates, R1, of dissolved phase 129Xe(sol) in 1:1 v/v 
H2O/ACN solution as a function of the concentration of various agents, [Rx], at 
293 K and 9.4 T field strength. Note that CrA-DOTA + Gd3+ (red data points 
and line) shows the relaxation data obtained more than 24 h after adding HCl 
to the solution with CrA-GdDOTA, causing Gd3+ to be expelled from the 
molecule.  Data point (i) shows effect of CrA-GdDOTA approximately 1 h after 
addition of HCl. (ii) After 24 h the reaction to CrA-DOTA + GdIII(sol) was 86 % 
complete as determined by HPLC (see supporting material). (iii) Reaction is 
96% complete after 96 h. Data points (i)-(iii) (i.e. crosses) are averages from 
three measurements  – all other data are from single measurements. 
Relaxivity values are reported in Fig. 3. 
 
 
The relaxivity of CrA-GdDOTA for 1H was very similar to that 
of GdDOTA. This was expected from Solomon-Bloembergen-
Morgan theory[12b] since the addition of the CrA group should 
have little effect on the number (q) of water molecules 
γ
γ 2
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coordinated to GdIII or their residence time. Furthermore, the 
rotational correlation time associated with the relatively small 
CrA-GdDOTA molecule is too short to significantly alter the 
relaxation behavior. 
 
Figure 3. Relaxivity, R1/[Rx], of various substances, Rx, for dissolved 
phase 129Xe(sol) and 1H (of H2O) at 293 K and 9.4 T in H2O/ACN (1:1 v/v) 
solution. Relaxivity was determined from linear fitting of data in Fig. 2 with 
0.0053 s-1mM-1 offset (i.e. experimental relaxivity of solvent). The dissolved 
phase 129Xe(sol) chemical shift 𝛿!"  dependence on [Rx] is obtained from linear 
fitting of 129Xe(sol) peak position using a 189.3 ppm (solvent) offset. A) 
Relaxivity of GdDOTA. B) Relaxivity model sensor molecule, i.e. a 
cryptophane-A linked to GdDOTA (Rx = CrA-GdDOTA). C) DOTA protonation 
at pH = 0 causing dissociation of GdIII from the molecule. (Rx = CrA-DOTA + 
GdIII3+) D) Rx = GdIII3+ in H2O/ACN solution at pH = 7 and E) Rx = GdIII-free 
precursor of the sensor molecule. 
 
A 1 mM CrA-GdDOTA solution corresponds to a 129Xe(sol) 
relaxation time of T1 = 2.4 s that is sufficiently short to affect the 
overall relaxation in vivo. Unlike HyperCEST, this effect does not 
require radiofrequency irradiation for saturation to accomplish 
depolarization. Rather, depolarization occurs as the 
consequence of the combined effect of relaxation in the bound 
phase (i.e. 129Xe in the cage) followed by chemical exchange 
leads to the fast decay of the dissolved phase signal. To 
deactivate the depolarization, the relaxation agent will need to 
be ‘turned off’ through selective chemical or biochemical 
cleavage of the paramagnetic center from the encapsulating 
cage. 
To demonstrate the deactivation concept, but also to further 
prove that accelerated 129Xe relaxation was indeed caused by 
the close vicinity of the paramagnetic metal to the encapsulated 
129Xe, HCl (37% v/v) was added to protonate DOTA and leach 
the GdIII ion out of the chelator moiety to form CrA-DOTA + 
Gd3+(sol) . This process, led to a 4.3 fold drop in the relaxivity for 
129Xe to 0.0955 ±0.0051 s-1mM-1 shown in Fig. 3C. This value is 
still 2 times higher than that found for GdDOTA in Fig. 3A, most 
likely because of increased contact of 129Xe(sol) with the 
unchelated paramagnetic metal ion (similarly effecting the 1H 
relaxation in Fig. 3C). In a control experiment the relaxivity of 
GdCl3 for 129Xe in H2O/ACN solution (Fig 3D, pH = 7) was found 
to be R1/[Rx] = 0.0847 s-1mM-1 , close to the value in Fig. 3C at 
pH = 0. 
Fig. 2 also shows the time behavior (i – iii) of the DOTA 
protonation and the associated change in relaxivity that took 
several days for completion. This time behavior was verified 
through HPLC and mass spectrometry (see Supporting 
Information). It demonstrates that the change in relaxivity was 
indeed caused by the separation of the GdIII center from the 
cryptophane cage and not by a pH dependence of the xenon in-
out exchange rate with the cryptophane cage, in agreement with 
previous literature studying pH effects.[15]    
Conclusions. The relaxation data generated in this study 
demonstrates a dramatic increase in relaxivity of a GdDOTA for 
129Xe when the complex is tethered to a cryptophane cage. This 
increase is the consequence of the prolonged duration of cage 
bound 129Xe in close vicinity to the paramagnetic metal center. 
The strong relaxation experienced by cage bound xenon is 
transferred through chemical exchange to the solvent phase 
129Xe. The dissolved phase 129Xe signal decays at a rate that is 
the average of the relaxation rate in the cage and the relaxation 
rate in the solvent, scaled by the duration that the xenon atoms 
remain in the two respective phases.  
As this hp 129Xe chemical exchange relaxation transfer 
mechanism can be disrupted by the separation of CrA cage from 
the paramagnetic metal, a specifically designed responsive 
contrast agent can give rise to a new switchable 129Xe 
depolarization based biosensor concept. Although this method 
may lack some of the intrinsic versatility of the HyperCEST 
concept, the presented responsive MRI contrast agent concept 
would not require high spectral resolution. In addition, switchable 
relaxation does not entail high power radiofrequency saturation 
that can be problematic for in vivo studies due to heat adsorption 
in tissue. Furthermore, the relaxation agent deactivation is 129Xe 
specific and does not affect proton T1 relaxation (compare Fig. 3, 
A and B) and standard 1H T1 relaxation maps should allow to 
probe for the presence of biosensors independent of the 
activation state. This should allow for differentiation of regions 
with higher concentration of deactivated biosensor from those 
with lower concentration of still active biosensor. Although both 
regions may result in similar 129Xe relaxation rates, the very 
different 1H relaxation behavior would enable correct 
interpretation.  
The design of future responsive hp 129Xe depolarization 
agents as potential biosensors deserves some consideration: In 
analogy to the r-6 dependence utilized in intramolecular Förster 
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resonance energy transfer (FRET),[16] the r-6 dependence of 
paramagnetic relaxation on distance r between the cage and the 
paramagnetic metal center could be exploited for sensors that 
operate through conformational changes or through a cleavable 
linker between the two groups. Enzymatic cleavage of the linker 
between paramagnetic GdDOTA and a 19F containing reporter 
group was previously utilized to deactivate paramagnetic T2 
relaxation, thereby reducing line broadening in thermally 
polarized 19F NMR.[17] Furthermore, enzymatic cleavage has 
been detected through a chemical shift based hp 129Xe 
biosensor.[18] Similarly, cleavable linkers between a 
paramagnetic group and cryptophane cage may provide a 
usable responsive hp 129Xe relaxation agents. The molecular 
design of the hp 129Xe depolarization based biosensors can be 
advanced through an increase in the number of captured xenon 
atoms, for example through the usage of multiple cryptophane 
cages or through capsides[19] that would also increase rotational 
correlation times. Both effects will likely increase the relaxivity of 
the activated state but not of the deactivated state. Finally, GdIII  
can be substituted by other paramagnetic groups with stronger 
relaxation properties such as Mn(II) nanoparticles.[20] 
 
 
Experimental Section 
As described in detail in the Supporting Information, the model sensor 
CrA-GdDOTA was synthesized from a DOTA chelator, modified with a 
short linker, and cryptophanol. Cryptophanol was synthesized as 
previously reported by Bertault and co-workers,[7d] while the DOTA-linker 
was simply obtained by reacting an appropriately protected DO3A with a 
short bisamide linker with alpha-bromoacetyl as terminal. The 
cryptophanol was then reacted with the alpha-bromoacetyl group to form 
an ether. After deprotection of the DOTA carboxylic groups, the GdIII 
cation was successfully chelated, yielding the desired compound CrA-
GdDOTA. 
All NMR relaxation measurements were obtained at a temperature of 293 
K at 9.4 T field strength. Hp 129Xe was produced through spin exchange 
optical pumping (SEOP) using a custom–built instrument described 
elsewhere.[21] Prior to hp 129Xe delivery in each experiment the solution 
was purged with N2 for 2 min to ensure the removal of any residual O2. 
The hp gas mixture was then delivered under continuous flow SEOP 
conditions for 45 s at 40 ml/min into the relaxation agent containing 
solution. After flow stoppage, the dissolved phase hp 129Xe T1 relaxation 
was measured through a sequence of 16 constant flip angle (12°) 
experiments.[22] A standard inversion recovery sequence was used to 
obtain the 1H T1 relaxation of H2O. 
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